Thomas Graham, Alan, Irving Kahns
Kahn Brothers Group
Kahn Brothers Group Organon & Co stake
total: 111
Kahn Brothers Group OGN trades
- Total transactions:
- 20
- New positions:
- 1
- Added:
- 9
- Reduced:
- 10
- Held since:
- 2021 Q2
- Held for:
- 20 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Kahn Brothers Group holds 5,536,993 Organon & Co (OGN) shares with a market value of roughly $33.17M accounting for 5.88% of the overall portfolio. To date, the estimated cost basis is nearly $12.55 for "buy" trades and estimated average "sell" price is $15.45. Kahn Brothers Group first purchased OGN in 2021 Q2, initially acquiring 71,622 shares. Since the initial investment in Organon & Co (OGN), Kahn Brothers Group has made 19 more transactions.
When did Kahn Brothers Group buy Organon & Co (OGN)?
Kahn Brothers Group first invested in Organon & Co (OGN) in 2021 Q2 at the reported quarter-end price of $30.26 per share.
What's the cost basis of Kahn Brothers Group's OGN stake?
The estimated cost basis for Organon & Co (OGN) stake is around $12.55 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $12.55
- Weighted AVG sell price:
- $15.44
Kahn Brothers Group's historical trades in Organon & Co
20 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
5.88%
|
5,536,993
|
$5.99
|
$33,166,588
|
+52.56% (+1,907,542)
|
+2.03%
|
|
2025 Q4
|
4.61%
|
3,629,451
|
$7.17
|
$26,023,163
|
+0.35% (+12,606)
|
+0.02%
|
|
2025 Q3
|
7.26%
|
3,616,845
|
$10.68
|
$38,627,904
|
+3.63% (+126,695)
|
+0.25%
|
|
2025 Q2
|
6.78%
|
3,490,150
|
$9.68
|
$33,784,652
|
+39.98% (+996,766)
|
+1.94%
|
|
2025 Q1
|
7.51%
|
2,493,384
|
$14.89
|
$37,126,423
|
+59.09% (+926,111)
|
+2.79%
|
|
2024 Q4
|
5.08%
|
1,567,273
|
$14.92
|
$23,383,367
|
-14.60% (-267,920)
|
-0.69%
|
|
2024 Q3
|
6.05%
|
1,835,193
|
$19.13
|
$35,107,592
|
+10.49% (+174,170)
|
+0.57%
|
|
2024 Q2
|
5.78%
|
1,661,023
|
$20.70
|
$34,382,763
|
+40.74% (+480,819)
|
+1.67%
|
|
2024 Q1
|
3.29%
|
1,180,204
|
$18.80
|
$22,187,575
|
+3,242.41% (+1,144,894)
|
+3.19%
|
|
2023 Q4
|
0.08%
|
35,310
|
$14.42
|
$509,168
|
-31.23% (-16,036)
|
-0.04%
|
|
2023 Q3
|
0.14%
|
$17.37
|
-14.13% (-8,452)
|
|||
|
2023 Q2
|
0.18%
|
$20.80
|
-2.96% (-1,821)
|
|||
|
2023 Q1
|
0.21%
|
$23.51
|
-1.62% (-1,015)
|
|||
|
2022 Q4
|
0.23%
|
$27.92
|
+0.59% (+366)
|
|||
|
2022 Q3
|
0.23%
|
$23.41
|
-6.45% (-4,290)
|
|||
|
2022 Q2
|
0.30%
|
$33.75
|
-1.26% (-846)
|
|||
|
2022 Q1
|
0.30%
|
$34.94
|
-2.13% (-1,466)
|
|||
|
2021 Q4
|
0.29%
|
$30.45
|
-1.84% (-1,294)
|
|||
|
2021 Q3
|
0.32%
|
$32.79
|
-2.04% (-1,458)
|
|||
|
2021 Q2
|
0.31%
|
$30.26
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.